⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
EPHA4 Targeting in Ovarian Aging / POI
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-28 — Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.: Proteomic Mendelian randomization + colocalization across cohorts prioritized EPHA4 as a causal POI target; validated as dysregulated in cisplatin-injured mouse and human granulosa cells, with molecular docking showing cycloheximide binding at −7.8 kcal/mol and stable MD simulations (no human outcome data). [human-observational] (novelty: 3)
Open questions
Related
Contributing findings
Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.
28-aug-2026
novelty 3
per-area 3
strengthens